权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Contribution of Central Nervous System Demyelination to Bladder Dysfuntion

中枢神经系统脱髓鞘对膀胱功能障碍的影响

基本信息

批准号：
10352892
负责人：
Stephen J Crocker
金额：
$ 45.1万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-30 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10352892
关键词：
Address Affect Age Animals Bladder Bladder Control Bladder Diseases Bladder Dysfunction Brain Brain Stem CASP9 gene Chronic Clinical Clinical effectiveness Cognition Complex Conscious Cuprizone Data Demyelinations Development Disease Disease Progression Etiology Event Foundations Frequencies Functional disorder Grant Hospitalization Human Impairment Incontinence Inflammation Interdisciplinary Study Investigation Knockout Mice Knowledge Lesion Link Lower urinary tract Maps Measures Mediating Memory Modeling Monitor Multiple Sclerosis Mus Muscarinic Antagonists Muscarinic M1 Receptor Myelin Natural regeneration Nervous System control Neuraxis Oligodendroglia Outcome Study Pathologic Patient Agents Patients Pharmaceutical Preparations Phenotype Pontine structure Prevalence Recording of previous events Recovery Reflex action Regulation Role Scientist Spinal Surrogate Markers Symptoms Testing Therapeutic Therapeutic Effect Treatment Efficacy Urge Incontinence Urinary Incontinence Urinary tract infection Urination Urine Urologic Surgeon central nervous system demyelinating disorder chronic demyelination conditional knockout conditional mutant defined contribution disorder control efficacy evaluation experience illness length improved learned behavior motor learning mouse model multidisciplinary multiple sclerosis patient myelination novel patient population prevent remyelination restoration sex therapeutic effectiveness therapeutic target treatment effect urinary

项目摘要

Abstract Myelination in the CNS is important for many higher order brain functions such as cognition, memory and complex motor learning behaviors. Loss of CNS myelination in diseases like multiple sclerosis (MS) represents a critical pathological event. Chronic demyelination is linked with disease progression making remyelination a therapeutic target for addressing progressive MS. Loss of bladder control is a pervasive issue among multiple sclerosis (MS) patients. It is also a leading cause of hospitalization among this patient population. It is estimated that nearly all MS patients will experience lower urinary tract dysfunction. Since symptom prevalence increases with disease duration, every MS patients will eventually experience urgency to urinate, urinary incontinence, frequency of urination, and/or retention of urine. Urinary dysfunction in MS patients remain a difficult therapeutic challenge because the etiology of bladder dysfunction among these patients is not well understood. While specific bladder dysfunction likely varies from patient-to-patient and with age, sex and history of urinary tract infections, it is generally thought that demyelination indirectly affects the bladder reflex and contributes to problems of urine storage (frequency) and emptying (retention). However, our new data presented in this proposal support bladder dysfunction as a direct corollary of CNS demyelination. Further, we hypothesize that CNS myelination may underlie the therapeutic efficacy of antimuscarinic agents which are mainstay therapy for patients with neurogenic and non-neurogenic bladder control disorders. Interestingly, an in parallel with the therapeutic effects of anti-muscarinic effects on remyelination in human MS patients, these agents take several weeks to become maximally effective among even non-MS patients with urinary disorders. Because anti-muscarinic agents have been implicated as a means to stimulate oligodendrocyte maturation, and these agents can stimulate central nervous system (CNS) remyelination in MS patients, we propose that CNS myelination underlies the development of bladder dysfunction. Therefore, bladder function could therefore serve as a surrogate marker for evaluating the efficacy of CNS remyelinating therapies. Hence, the objective of this study will be to determine whether CNS myelination underlies the therapeutic effects of anti-muscarinic treatments on bladder function in a model of CNS demyelination. We hypothesize that CNS demyelination is responsible for bladder dysfunction and the clinical benefits of muscarinic antagonists that are clinically measured as enhanced control of bladder function, are mediated through remyelination by oligodendrocytes. The results of this study will address several salient questions: (Aim 1) we will determine whether CNS demyelination impairs bladder function, (Aim 2). we will establish whether oligodendrocytes are required for the anti-muscarinic treatment effects on bladder dysfunction. Together these data are expected to impact our fundamental understanding of how the CNS, and CNS myelination specifically, contribute to the regulation urinary function and therein generate new knowledge on the basis of bladder dysfunction in disease.